Merit Medical Systems, Inc. (MMSI)

Several events have impacted Merit Medical Systems, Inc. stock price in the past six months. Merit Medical exceeded Q3 2025 forecasts, leading to a stock increase. The company reported efficacy results from the WAVE trial. Merit Medical reported Q4 and full year 2025 results and provided 2026 guidance. Merit Medical launched the Resilience Through-the-Scope Esophageal Stent. Medtronic announced a distribution agreement with Merit Medical for the ViaVerte basivertebral nerve ablation system. Merit Medical acquired View Point Medical, Inc. Merit Medical is scheduled to release its financial results for Q1 2026. The stock has experienced mixed returns over recent periods. Analysts generally maintain a "Moderate Buy" consensus.

While the search results mention "MMSI Seasonality" and the display of mean and median monthly returns to identify seasonal patterns, specific details regarding the nature or drivers of demand seasonality for Merit Medical Systems' products and services were not explicitly provided. The company's revenue has shown consistent year-over-year growth.

Merit Medical Systems, Inc., founded in 1987, develops, manufactures, and distributes proprietary disposable medical devices. The company operates in the healthcare sector, focusing on medical instruments and supplies used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. The company reports two main segments: Cardiovascular and Endoscopy. The Cardiovascular segment includes products for diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases. The Endoscopy segment focuses on gastroenterology and pulmonology devices.

Merit Medical Systems has a significant global presence, serving client hospitals and physicians worldwide and employing approximately 7,000 to 7,500 people. Its principal offices are in South Jordan, Utah, which also houses a manufacturing plant. Additional manufacturing plants are located in Galway, Ireland, and Angleton (Pearland), Texas. A distribution center is maintained in Maastricht, The Netherlands. Merit Medical has facilities and a sales and clinical support team across numerous countries.

Merit Medical Systems strives to be a customer-focused company in healthcare, aiming to innovate and deliver products that improve lives globally. The company emphasizes its mission to create innovative medical devices and its commitment to quality. In 2023, Merit Medical completed its "Foundations for Growth" program, which strengthened profitability, drove top-line growth, and fostered continued innovation, leading to record-setting revenue and strong shareholder returns. No specific negative events significantly impacted Merit Medical Systems' brand reputation within the past year.

Merit Medical Systems, Inc. stock ownership is primarily institutional, with approximately 85.0% to 94.86% held by institutional investors including BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Individual investors, including insiders, hold a smaller percentage of the company's stock. Fred P. Lampropoulos, a co-founder, President/CEO, and board chairman, is the largest individual shareholder.